Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Attachment development and learning in ADHD: the role of dopamine
2025-525122-35-00Phase 4Authorised
- Sponsor
- UZ Leuven
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of methylphenidate in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by UZ Leuven. Primary endpoints: Children’s instrumental responding to caregiver-related cues compared to neutral cues, Children’s trust learning and support-seeking behavior and 2 more. Planned start Sep 2026; status: authorised.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2025-525122-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525122-35-00.